According to a new report, published by KBV research, The Global Heart Failure POC And LOC Devices Market size is expected to reach $252.9 million by 2030, rising at a market growth of 16.4% CAGR during the forecast period.
The Metabolomic Testing segment is showcasing a CAGR of 17.1% during (2023 - 2030). Metabolomic profiling is valuable in drug development to understand the impact of pharmaceutical interventions on metabolism. It helps identify potential drug targets, evaluate drug efficacy, and assess drug safety by monitoring changes in metabolic pathways. Metabolomic testing is used to study the effects of diet on metabolism. It provides insights into how the body processes and utilizes nutrients, facilitating the development of personalized nutrition plans.
The Clinics segment is leading the Global Heart Failure POC And LOC Devices Market by End Use in 2022; thereby, achieving a market value of $88.7 Million by 2030. POC testing has effectively addressed critical requirements across diverse healthcare environments. Healthcare professionals in outpatient clinics attempt to replace curative medications with prognostic disease testing to determine the likelihood of heart failure. More outpatient clinics are implementing POC devices to diagnose heart failure promptly and accurately, enabling informed treatment decisions. Consequently, clinics have risen to prominence compared to other end-use settings.
The Array-Based Systems segment is experiencing a CAGR of 16.8% during (2023 - 2030). DNA molecules representing genes or genomic regions are immobilized on a solid substrate, allowing the simultaneous analysis of thousands of genes. Proteins or peptides are arrayed on a solid support, enabling the investigation of protein binding events and functional protein analyses. Small tissue cores from different samples are arrayed onto a single slide for simultaneous analysis. Advancements in array-based systems enable the analysis of individual cells, providing insights into cellular heterogeneity.
The North America region dominated the Global Heart Failure POC And LOC Devices Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $98.1 Million by 2030. The Europe region is poised to grow a CAGR of 16.2% during (2023 - 2030). Additionally, The Asia Pacific region would register a CAGR of 17.3% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/heart-failure-poc-and-loc-devices-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Siemens Healthineers AG (Siemens AG), Danaher Corporation, F. Hoffmann-La Roche Ltd., BioMerieux S.A., QuidelOrtho Corporation, Trinity Biotech Plc, Jant Pharmacal Corporation, Abaxis, Inc. (Zoetis Services LLC) and Werfen, S.A.
By Test Type
By End Use
By Technology
By Geography
Companies Profiled
Unique Offerings 
